ALX Oncology Holdings Inc. (ALXO)
$0.89-9.18%Close
SELLCRISIS · day 21
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $120M
- Beta
- 0.40
- P/E (TTM)
- -0.79
- Short % float
- 5.30%
- Days to cover
- 3.8
- SI change
- -9.6%
- 1W
- -21.24%
- 1M
- -52.91%
- vs SPY 1W
- -21.10%
- vs SPY 1M
- -55.42%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 13
- VALUE
- 12
- GROWTH
- 47
- GARP
- 6
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-54.2%
REV YoY-
ROE-90.3%
EPS YoY-
ROA-50.3%
GROSS0
OP0
NET0
[VALUATION]
P/E TTM-0.79
P/E FWD-
SECTOR PE20.48
INDUSTRY PE13.99
P/B0.89
P/FCF-
EV/EBITDA-1.36
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E7.13
ALTMAN Z-
CURR RATIO9.71
ND/EBITDA-
BETA0.40
Company news
FAQ
- What is LOPJLB’s current signal on ALXO?
- LOPJLB’s latest quantitative signal on ALX Oncology Holdings Inc. (ALXO) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is ALXO in?
- ALX Oncology Holdings Inc. (ALXO) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does ALX Oncology Holdings Inc. (ALXO) do?
- ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The companyâs lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic development as a combination therapy with other anti-cancer agents, including ASPEN-06, under phase 2 clinical study for treating Gastric/GEJ cancer. It has colla…